Table 4.
Cox proportional hazard model for on-treatment mortality by clinical characteristics and serum biomarkers levels in patients with pulmonary TBa.
| Univariate | Multivariate | |||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age | 1.09 (1.02–1.15) | 0.006 | 1.08 (1.01–1.15) | 0.019 |
| Male | 1.75 (0.38–8.08) | 0.467 | ||
| BMI | 0.68 (0.53–0.87) | 0.002 | 0.74 (0.58–0.96) | 0.024 |
| smoking | 1.28 (0.43–3.81) | 0.663 | ||
| Prior TB treatment | 1.19 (0.24–6.03) | 0.833 | ||
| Diabetes | 0.87 (0.19–4.01) | 0.853 | ||
| Renal insufficiency | 2.19 (0.28–17.15) | 0.454 | ||
| COPD | 5.01 (0.92–27.25)) | 0.107 | ||
| Malignancy | 3.02 (0.86–10.62) | 0.101 | ||
| sTREM1 >260 pg/mL | 8.93 (2.44–32.69) | 0.001 | 13.93 (1.57–58.59) | 0.018 |
| sTREM2 >99 pg/mL | 5.26 (1.59–17.40) | 0.007 | 0.31 (0.04–2.20) | 0.240 |
| CRP >2.6 mg/L | 5.85 (1.79–19.14) | 0.004 | 7.85 (1.31–47.05) | 0.024 |
aHazard ratio and 95% confidence interval were derived from the Cox proportional-hazards regression model.
HR, hazard ratio; CI, confidence interval; COPD, chronic obstructive pulmonary disorder; sTREM, soluble triggering receptor expressed on myeloid cells; CRP, C-reactive protein.